Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis

Artificial Organs

Volumn 38, Issue 10, 2014, Pages 888-893

  Krieter, Detlef H ^a   Devine, Eric ^b   Wanner, Christoph ^a   Storr, Markus ^c   Krause, Bernd ^c   Lemke, Horst Dieter ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b eXcorLab GmbH   (Germany)

^c Gambro Dialysatoren GmbH   (Germany)

Author keywords

Bortezomib; Dexamethasone; High cutoff dialysis; Multiple myeloma; Protein binding; Thalidomide

Indexed keywords

BIOCHEMISTRY; BLOOD; CHEMOTHERAPY; HEMODIALYZERS; METABOLISM; PROTEINS; UREA;

BORTEZOMIB; DEXAMETHASONES; HAEMODIALYSIS; HIGH-CUTOFF DIALYSIS; IN-VITRO; K-VALUES; MATHEMATICAL SIMULATIONS; MULTIPLE MYELOMA; PROTEIN-BINDING; THALIDOMIDE;

DIALYSIS;

ALBUMIN; BORTEZOMIB; DEXAMETHASONE; SODIUM CHLORIDE; THALIDOMIDE; UREA; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD FLOW VELOCITY; CANCER CHEMOTHERAPY; DIALYSATE; DIALYZER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; HEMODIALYSIS; IN VITRO STUDY; MATHEMATICAL MODEL; MULTIPLE MYELOMA; PLASMA CLEARANCE; ULTRAFILTRATION; UREA BLOOD LEVEL; ACUTE KIDNEY INJURY; AGED; COMPLICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; THEORETICAL MODEL;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIPLE MYELOMA; PYRAZINES; RENAL DIALYSIS; THALIDOMIDE;

EID: 84916217584     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12248     Document Type: Article

References (28)

1. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992;89:630-639.
2. Haynes RJ, Read S, Collins GP, etal. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant 2010;25:419-426.
3. Hutchison CA, Cockwell P, Reid S, etal. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-895.
4. Hutchison CA, Cockwell P, Stringer S, etal. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22:1129-1136.
5. Bachmann U, Schindler R, Storr M, etal. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus 2008;1:106-108.
6. Hutchison CA, Bradwell AR, Cook M, etal. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-754.
7. Hutchison CA, Heyne N, Airia P, etal. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 2012;27:3823-3828.
8. Heyne N, Denecke B, Guthoff M, etal. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 2012;91:729-735.
9. Roussou M, Kastritis E, Christoulas D, etal. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395-1397.
10. Ludwig H, Avet-Loiseau H, Bladé J, etal. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012;17:592-606.
11. Hutchison CA, Cook M, Heyne N, etal. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008;9:55.
12. Peets EA, Staub M, Symchowicz S. Plasma binding of betamethasone-3H, dexamethasone-3H, and cortisol-14C-a comparative study. Biochem Pharmacol 1969;18:1655-1663.
13. Janssen-Cilag. VELCADE, product information. 2012.
14. Eriksson T, Björkman S, Roth B, Fyge A, Höglund P. Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998;10:223-228.
15. Meyer T, Leeper EC, Barlett DW, etal. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 2004;15:1927-1935.
16. Meyer TW, Paettie JWT, Miller JD, etal. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 2007;18:868-874.
17. De Smet R, Dhondt A, Eloot S, etal. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007;22:2006-2012.
18. Sargent JA, Gotch FA. Principles and biophysics of dialysis. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, eds. Replacement of Renal Function by Dialysis, 4th Edition. Dordrecht/Boston/London: Kluwer Academic Publishers, 1996;34-102.
19. Krieter DH, Hackl A, Rodriguez A, etal. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010;25:212-218.
20. Pekol T, Daniels JS, Labutti J, etal. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771-777.
21. Lee HS, Kim YS, Kim K, etal. Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. J Korean Med Sci 2013;28:80-86.
22. Schwinn DA, Schafer SL. Basic principles of pharmacology related to anesthesia. In: Miller RD, ed. Anesthesia, 5th Edition. Philadelphia: Churchill Livingstone, 2000;15-48.
23. Cummings DM, Larijani GE, Conner DP, Ferguson RK, Rocci ML Jr. Characterization of dexamethasone binding in normal and uremic human serum. DICP 1990;24:229-231.
24. Naik PN, Chimatadar SA, Nandibewoor ST. Interaction between a potent corticosteroid drug - dexamethasone with bovine serum albumin and human serum albumin: a fluorescence quenching and Fourier transformation infrared spectroscopy study. J Photochem Photobiol B 2010;100:147-159.
25. Van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet 2009;24:300-307.
26. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005;20:309-323.
27. Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. J Biol Chem 2000;275:38731-38738.
28. Sakai T, Takadate A, Otagiri M. Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995;18:1755-1761.